Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications

Background. Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. Methods. Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated ov...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2022-03, Vol.2022, p.4112016-9
Main Authors: Huang, He, Zhou, Shuping, Lin, Hongdou, Guo, Wenjian, Lin, Ying, Yao, Ronxin, He, Licai, Yu, Kang, Li, Qian
Format: Article
Language:English
Subjects:
Apoptosis
B cells
Biotechnology industry
Bone marrow
Cell growth
Chemotherapy
Creatinine
DNA damage
Ethylenediaminetetraacetic acid
Gene expression
Genes
Genetic aspects
Genomes
Health aspects
Hospitals
Hybridization
Inhibitor drugs
Kinases
Laboratories
Medical prognosis
Medical research
Medicine, Experimental
Multiple myeloma
Patients
Plasma
Proteins
Software
Targeted cancer therapy
Tumor proteins
Vincristine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c433t-6318a4aea234ac6c6233e05d16b5259e4589fa49991877023dbb2f7ecfff21963
container_end_page 9
container_issue
container_start_page 4112016
container_title Journal of oncology
container_volume 2022
creator Huang, He
Zhou, Shuping
Lin, Hongdou
Guo, Wenjian
Lin, Ying
Yao, Ronxin
He, Licai
Yu, Kang
Li, Qian
description Background. Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. Methods. Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated overall patient survival and assessed the cytotoxicity of imatinib against MM cells using a CCK8 assay. Results. ABL gene amplification was detected in 67 patients (66.3%). However, ABL gene amplification was not associated with clinical features, cytogenetic abnormalities (c-Myc amplification, IGH rearrangement, RB1 deletion, p53 deletion, or 1q21 amplification), or overall survival. ABL amplification in MM cell lines (LP-1 and U266) was revealed by FISH. Furthermore, the ABL protein was easily detectable in MM cell lines and some tumor cells by western blotting. A CCK8 assay indicated limited cytotoxicity of imatinib against MM cells. Conclusions. Our study firstly discussed ABL gene amplification was prevalent in MM cells, and we believe that the ABL gene would potentially be a useful target in the treatment of combination strategy for MM with ABL amplification in the future.
doi_str_mv 10.1155/2022/4112016
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8941557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A698473989</galeid><sourcerecordid>A698473989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-6318a4aea234ac6c6233e05d16b5259e4589fa49991877023dbb2f7ecfff21963</originalsourceid><addsrcrecordid>eNp90c1rFDEYBvBBFFurN88S8CLo2nxPchHWUrWwpZd6DtnMm25KJhmTmUr_e2fYtVYPnhLIL0_y8jTNa4I_EiLEKcWUnnJCKCbySXNMpGpXigv89NH-qHlR6y3GkmMtnzdHTDBOORHHzdX5XeggOUA-F7T-vEHrfojBB2fHkBMKCV1OcQxDBHR5DzH3FtnUoesdFDvANAaHLpYbe19fNs-8jRVeHdaT5vuX8-uzb6vN1deLs_Vm5Thj40oyoiy3YCnj1kknKWOARUfkVlChgQulveVaa6LaFlPWbbfUt-C895RoyU6aT_vcYdr20DlIY7HRDCX0ttybbIP5-ySFnbnJd0bpeW7RzgHvDgEl_5igjqYP1UGMNkGeqqGScyZxy8lM3_5Db_NU0jzeopgiDGP9R93YCCYkn-d33RJq1lIr3jKtFvVhr1zJtRbwD18m2Cx9mqVPc-hz5m8ej_mAfxc4g_d7sAupsz_D_-N-AZsnpb4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2643813009</pqid></control><display><type>article</type><title>Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Huang, He ; Zhou, Shuping ; Lin, Hongdou ; Guo, Wenjian ; Lin, Ying ; Yao, Ronxin ; He, Licai ; Yu, Kang ; Li, Qian</creator><contributor>Raghavamenon, Achuthan Chathrattil</contributor><creatorcontrib>Huang, He ; Zhou, Shuping ; Lin, Hongdou ; Guo, Wenjian ; Lin, Ying ; Yao, Ronxin ; He, Licai ; Yu, Kang ; Li, Qian ; Raghavamenon, Achuthan Chathrattil</creatorcontrib><description>Background. Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. Methods. Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated overall patient survival and assessed the cytotoxicity of imatinib against MM cells using a CCK8 assay. Results. ABL gene amplification was detected in 67 patients (66.3%). However, ABL gene amplification was not associated with clinical features, cytogenetic abnormalities (c-Myc amplification, IGH rearrangement, RB1 deletion, p53 deletion, or 1q21 amplification), or overall survival. ABL amplification in MM cell lines (LP-1 and U266) was revealed by FISH. Furthermore, the ABL protein was easily detectable in MM cell lines and some tumor cells by western blotting. A CCK8 assay indicated limited cytotoxicity of imatinib against MM cells. Conclusions. Our study firstly discussed ABL gene amplification was prevalent in MM cells, and we believe that the ABL gene would potentially be a useful target in the treatment of combination strategy for MM with ABL amplification in the future.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/4112016</identifier><identifier>PMID: 35342415</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Apoptosis ; B cells ; Biotechnology industry ; Bone marrow ; Cell growth ; Chemotherapy ; Creatinine ; DNA damage ; Ethylenediaminetetraacetic acid ; Gene expression ; Genes ; Genetic aspects ; Genomes ; Health aspects ; Hospitals ; Hybridization ; Inhibitor drugs ; Kinases ; Laboratories ; Medical prognosis ; Medical research ; Medicine, Experimental ; Multiple myeloma ; Patients ; Plasma ; Proteins ; Software ; Targeted cancer therapy ; Tumor proteins ; Vincristine</subject><ispartof>Journal of oncology, 2022-03, Vol.2022, p.4112016-9</ispartof><rights>Copyright © 2022 He Huang et al.</rights><rights>COPYRIGHT 2022 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2022 He Huang et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 He Huang et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c433t-6318a4aea234ac6c6233e05d16b5259e4589fa49991877023dbb2f7ecfff21963</cites><orcidid>0000-0003-3614-9002 ; 0000-0003-2195-3700 ; 0000-0002-1211-2830 ; 0000-0002-8144-0782 ; 0000-0001-9946-9869 ; 0000-0002-1607-5619 ; 0000-0001-5359-8534 ; 0000-0003-3593-4535 ; 0000-0002-8873-3326</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2643813009/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2643813009?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35342415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Raghavamenon, Achuthan Chathrattil</contributor><creatorcontrib>Huang, He</creatorcontrib><creatorcontrib>Zhou, Shuping</creatorcontrib><creatorcontrib>Lin, Hongdou</creatorcontrib><creatorcontrib>Guo, Wenjian</creatorcontrib><creatorcontrib>Lin, Ying</creatorcontrib><creatorcontrib>Yao, Ronxin</creatorcontrib><creatorcontrib>He, Licai</creatorcontrib><creatorcontrib>Yu, Kang</creatorcontrib><creatorcontrib>Li, Qian</creatorcontrib><title>Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Background. Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. Methods. Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated overall patient survival and assessed the cytotoxicity of imatinib against MM cells using a CCK8 assay. Results. ABL gene amplification was detected in 67 patients (66.3%). However, ABL gene amplification was not associated with clinical features, cytogenetic abnormalities (c-Myc amplification, IGH rearrangement, RB1 deletion, p53 deletion, or 1q21 amplification), or overall survival. ABL amplification in MM cell lines (LP-1 and U266) was revealed by FISH. Furthermore, the ABL protein was easily detectable in MM cell lines and some tumor cells by western blotting. A CCK8 assay indicated limited cytotoxicity of imatinib against MM cells. Conclusions. Our study firstly discussed ABL gene amplification was prevalent in MM cells, and we believe that the ABL gene would potentially be a useful target in the treatment of combination strategy for MM with ABL amplification in the future.</description><subject>Apoptosis</subject><subject>B cells</subject><subject>Biotechnology industry</subject><subject>Bone marrow</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Creatinine</subject><subject>DNA damage</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genomes</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Hybridization</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Multiple myeloma</subject><subject>Patients</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Software</subject><subject>Targeted cancer therapy</subject><subject>Tumor proteins</subject><subject>Vincristine</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp90c1rFDEYBvBBFFurN88S8CLo2nxPchHWUrWwpZd6DtnMm25KJhmTmUr_e2fYtVYPnhLIL0_y8jTNa4I_EiLEKcWUnnJCKCbySXNMpGpXigv89NH-qHlR6y3GkmMtnzdHTDBOORHHzdX5XeggOUA-F7T-vEHrfojBB2fHkBMKCV1OcQxDBHR5DzH3FtnUoesdFDvANAaHLpYbe19fNs-8jRVeHdaT5vuX8-uzb6vN1deLs_Vm5Thj40oyoiy3YCnj1kknKWOARUfkVlChgQulveVaa6LaFlPWbbfUt-C895RoyU6aT_vcYdr20DlIY7HRDCX0ttybbIP5-ySFnbnJd0bpeW7RzgHvDgEl_5igjqYP1UGMNkGeqqGScyZxy8lM3_5Db_NU0jzeopgiDGP9R93YCCYkn-d33RJq1lIr3jKtFvVhr1zJtRbwD18m2Cx9mqVPc-hz5m8ej_mAfxc4g_d7sAupsz_D_-N-AZsnpb4</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Huang, He</creator><creator>Zhou, Shuping</creator><creator>Lin, Hongdou</creator><creator>Guo, Wenjian</creator><creator>Lin, Ying</creator><creator>Yao, Ronxin</creator><creator>He, Licai</creator><creator>Yu, Kang</creator><creator>Li, Qian</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3614-9002</orcidid><orcidid>https://orcid.org/0000-0003-2195-3700</orcidid><orcidid>https://orcid.org/0000-0002-1211-2830</orcidid><orcidid>https://orcid.org/0000-0002-8144-0782</orcidid><orcidid>https://orcid.org/0000-0001-9946-9869</orcidid><orcidid>https://orcid.org/0000-0002-1607-5619</orcidid><orcidid>https://orcid.org/0000-0001-5359-8534</orcidid><orcidid>https://orcid.org/0000-0003-3593-4535</orcidid><orcidid>https://orcid.org/0000-0002-8873-3326</orcidid></search><sort><creationdate>20220315</creationdate><title>Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications</title><author>Huang, He ; Zhou, Shuping ; Lin, Hongdou ; Guo, Wenjian ; Lin, Ying ; Yao, Ronxin ; He, Licai ; Yu, Kang ; Li, Qian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-6318a4aea234ac6c6233e05d16b5259e4589fa49991877023dbb2f7ecfff21963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Apoptosis</topic><topic>B cells</topic><topic>Biotechnology industry</topic><topic>Bone marrow</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Creatinine</topic><topic>DNA damage</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genomes</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Hybridization</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Multiple myeloma</topic><topic>Patients</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Software</topic><topic>Targeted cancer therapy</topic><topic>Tumor proteins</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, He</creatorcontrib><creatorcontrib>Zhou, Shuping</creatorcontrib><creatorcontrib>Lin, Hongdou</creatorcontrib><creatorcontrib>Guo, Wenjian</creatorcontrib><creatorcontrib>Lin, Ying</creatorcontrib><creatorcontrib>Yao, Ronxin</creatorcontrib><creatorcontrib>He, Licai</creatorcontrib><creatorcontrib>Yu, Kang</creatorcontrib><creatorcontrib>Li, Qian</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, He</au><au>Zhou, Shuping</au><au>Lin, Hongdou</au><au>Guo, Wenjian</au><au>Lin, Ying</au><au>Yao, Ronxin</au><au>He, Licai</au><au>Yu, Kang</au><au>Li, Qian</au><au>Raghavamenon, Achuthan Chathrattil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2022-03-15</date><risdate>2022</risdate><volume>2022</volume><spage>4112016</spage><epage>9</epage><pages>4112016-9</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Background. Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. Methods. Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated overall patient survival and assessed the cytotoxicity of imatinib against MM cells using a CCK8 assay. Results. ABL gene amplification was detected in 67 patients (66.3%). However, ABL gene amplification was not associated with clinical features, cytogenetic abnormalities (c-Myc amplification, IGH rearrangement, RB1 deletion, p53 deletion, or 1q21 amplification), or overall survival. ABL amplification in MM cell lines (LP-1 and U266) was revealed by FISH. Furthermore, the ABL protein was easily detectable in MM cell lines and some tumor cells by western blotting. A CCK8 assay indicated limited cytotoxicity of imatinib against MM cells. Conclusions. Our study firstly discussed ABL gene amplification was prevalent in MM cells, and we believe that the ABL gene would potentially be a useful target in the treatment of combination strategy for MM with ABL amplification in the future.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>35342415</pmid><doi>10.1155/2022/4112016</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3614-9002</orcidid><orcidid>https://orcid.org/0000-0003-2195-3700</orcidid><orcidid>https://orcid.org/0000-0002-1211-2830</orcidid><orcidid>https://orcid.org/0000-0002-8144-0782</orcidid><orcidid>https://orcid.org/0000-0001-9946-9869</orcidid><orcidid>https://orcid.org/0000-0002-1607-5619</orcidid><orcidid>https://orcid.org/0000-0001-5359-8534</orcidid><orcidid>https://orcid.org/0000-0003-3593-4535</orcidid><orcidid>https://orcid.org/0000-0002-8873-3326</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-8450
ispartof Journal of oncology, 2022-03, Vol.2022, p.4112016-9
issn 1687-8450
1687-8450
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8941557
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central
subjects Apoptosis
B cells
Biotechnology industry
Bone marrow
Cell growth
Chemotherapy
Creatinine
DNA damage
Ethylenediaminetetraacetic acid
Gene expression
Genes
Genetic aspects
Genomes
Health aspects
Hospitals
Hybridization
Inhibitor drugs
Kinases
Laboratories
Medical prognosis
Medical research
Medicine, Experimental
Multiple myeloma
Patients
Plasma
Proteins
Software
Targeted cancer therapy
Tumor proteins
Vincristine
title Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A30%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20ABL%20Amplification%20in%20Multiple%20Myeloma%20and%20Therapeutic%20Implications&rft.jtitle=Journal%20of%20oncology&rft.au=Huang,%20He&rft.date=2022-03-15&rft.volume=2022&rft.spage=4112016&rft.epage=9&rft.pages=4112016-9&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/4112016&rft_dat=%3Cgale_pubme%3EA698473989%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c433t-6318a4aea234ac6c6233e05d16b5259e4589fa49991877023dbb2f7ecfff21963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2643813009&rft_id=info:pmid/35342415&rft_galeid=A698473989&rfr_iscdi=true